Mode
Text Size
Log in / Sign up
N/A N=18

Evaluation of Long-term Effect of Resonator Therapy on Parkinson's Disease (PD)

Parkinson's Disease

Enrolled (actual)
18
Serious AEs
0.0%
Results posted
Jul 2011
Primary outcome: Primary: Change in Parkinson's Disease Questionnaire-39 Single Index Score (PDQ-39SI)From Baseline to Study Endpoint of 11 Months — 4.96 scores on a scale

Study Design & Population

Study type
Observational
Phase
N/A
Interventions
Resonator Device (Device)
Age
Adult, Older Adult · 30+ yrs
Sex
All
Sponsor
pico-tesla Magnetic Therapies, LLC
Primary completion
Apr 2011

Outcome Measures

OutcomeResultp-value
PRIMARY
Change in Parkinson's Disease Questionnaire-39 Single Index Score (PDQ-39SI)From Baseline to Study Endpoint of 11 Months
4.96

Summary

An extension study for subjects with prior participation in previous resonator studies using low level magnetic fields to treat some of the symptoms of idiopathic Parkinson's Disease.

Eligibility Criteria

Inclusion Criteria

  • Prior participation in pico-tesla pilot studies: NCT00779155 & NCT00863226
  • Willing and able to abstain from partaking in non-essential new treatments for Parkinson's disease symptoms during the course of participation of the study.
  • Will and able to abstain from all non-essential new medications that could affect PD and/or any of its associated symptoms for the duration of the study.
  • Willing to notify the investigator right away of any changes in medication use or therapies that is prescribed and deemed necessary by the subjects physicians.
  • Adequate contraceptive measures for female subjects
  • Capable of giving full written informed consent

Exclusion Criteria

  • Not a participant in IRC#'s 07102 or 07021
  • No active brain tumors, strokes, hydrocephalus
  • Chronic pain not associated with PD
  • Any other condition which might prevent subject from comfortably sitting for 1.5 hours
  • Consumption of medications that can produce Parkinsonism type symptoms
  • Major psychiatric disturbance
  • Epilepsy
  • HIv and other autoimmune disorders
  • Cancer within last 2 years
  • History of ECt
  • Diabetic neuropathy
  • Uncontrolled HTN
  • Advanced Pulmonary disease
  • Known heart conditions such as repetitive history of cardiac arrythmias
  • Previous surgeries for PD
  • Prosthetics comprised of ferrous materials
  • Stents, only where there is also cardiac arrythmias, CHF, advanced valvular stenosis, unstable vital signs, extensive ischemic damage to heart muscle as a result of one or more heart attacks.
  • Pacemakers
  • Uncontrolled, unstable, or untreated medical illnesses which might potentially significantly affect the patient's health in the opinion of the investigator
  • Consumption of more than 21 alcoholic drinks per week
  • Pregnant, breast feeding or planning pregnancy
  • Developmental disability or cognitive impairment
  • Inability to maintain regular medication regime
  • Inability to abstain from partaking in new non-essential PD tx., or medications
  • Not willing to report physician mandated changes in medication and/or treatment
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00862537). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search